Trial · NCT04998786
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
NCT04998786, Phase 2, Active not recruiting, Nantes University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.". Trials, record NCT04998786. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04998786
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- NCT number
- NCT04998786
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 75 participants, actual
- Lead sponsor
- Nantes University Hospital
- Conditions
- Multiple Myeloma at First Relapse
- Interventions
- Ixazomib, Iberdomide, Dexamethasone Oral
- First posted
- 2021-08-10
- Last updated
- 2026-06-15
- Other registries' IDs
- eudract:2021-001587-13
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients have very good partial response (VGPR) or better | approximate 18 months | Using IMWG criteria |
| Secondary | Number of adverse events | approximate 18 months | Number of adverse events defined by Common Terminology Criteria for Adverse Events (v5) |
| Secondary | Number of responses | 3 months | Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and minor response (MR) will be evaluated according to IMWG |
| Secondary | Number of responses | 6 months | Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and minor response (MR) will be evaluated according to IMWG |
| Secondary | Number of the death | approximate 18 months | is defined as the time in months from inclusion to the date of death due to any cause. Subject alive will be censored at the last known alive date. |
| Secondary | Number of progression | approximate 18 months | is defined as the time in months from inclusion to the date of disease progression or death due to any cause, using IMWG criteria |
| Secondary | Percentage of time to progression | approximative 18 months | is defined as the time in months from inclusion to the date of disease progression or death due to any cause, using IMWG criteria |
| Secondary | Percentage of duration of response | approximative 18 months | is defined as the time from the first response (PR or better) to the date of disease progression or death due to any cause |
| Secondary | Percentage of duration of therapy | approximative 18 months | is defined as the time from treatment initiation to the last dose of therapy |
| Secondary | Percentage of time to response | approximative 18 months | according IMWG |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04998786
GET https://conductscience.org/api/trials/v1/NCT04998786/registered